Improving Suspendability of a Water-Insoluble Active in a Reconstitutable Powder for Oral Suspension
Jeff Williamson, Dr. Brad Gold, Allen Lawson, Keith Moore
To improve the suspendability of a water- insoluble active pharmaceutical ingredient (API) in a sorbitol- based reconstitutable powder for oral suspension formulation using two novel excipients Sentry™Polyox™WSR N80, NF (polyethylene oxide) and Avicel CL-611® NF (microcrystalline cellulose/carboxymethylcellulose sodium).
Reconstitutable powders for oral suspension are a widely accepted dosage form in the industry, especially with actives that may have stability issues when dispersed in an aqueous vehicle. Powders for oral suspension can be formulated with, but not limited to, various functional excipients such as suspending agents, binders, antimicrobial excipients, glidants, buffers, flavors, and sweeteners processed in a granulation and/or dry blend process.
In this case study, API (X) is a highly insoluble compound with a particle size of approximately 14 microns and targeted as a powder for oral suspension dosage form. Sentry™Polyox™WSR N80, NF (polyethylene oxide) and Avicel CL-611® NF (microcrystalline cellulose/carboxymethylcellulose sodium) were added in the proposed formulation in order to explore their nominal concentrations to improve suspendability of the active , feasibility of processing, and impact on physical (i.e. sedimentation rate, viscosity) and chemical analyses (API assay).
Once the final formulation was selected, the POS formulation was processed using conventional pharmaceutical processing equipment and formulation techniques in both small scale and large scale quantities.
An API (X), with limited aqueous solubility and distinct color, was formulated in a sorbitol-based reconstitutable powder for oral suspension. The initial formulation was reasonably unsuccessful in maintaining a suitable suspendability of the active. Sentry™Polyox™WSR N80, NF and Avicel CL-611® NF were added to the formulation in an attempt to physically increase the suspendability of the active when compared to control.
The first formulation was evaluated using Sentry™Polyox™WSR N80, NF at concentrations of 1-2% w/v of reconstituted product. In a separate formulation, Avicel CL-611® NF was added in concentrations of 1-2% w/v of reconstituted product.
Polyethylene Oxide, NF
(Sentry™ Polyox™ WSR N80 NF, Dow Chemical)
Function: Mucoadhesive, tablet binder, thickening agent
Microcrystalline Cellulose and Caboxymethylcellulose Sodium, NF
(Avicel CL-611 ®, FMC Biopolymer)
Function: Coating agent, tablet and capsule disintegrant, tablet binder, stabilizing agent, suspending agent, viscosity increasing agent
DISCUSSION AND CONCLUSIONS
Sentry™Polyox™WSR N80, NF and Avicel CL-611® NF were selected in this case study due to their rapid rate of hydration and functional classification. As we have seen, Tables 1 and 2 (along with Figures 1 and 2) show the increased suspendability of API (X) over time when Sentry™Polyox™WSR N80, NF and Avicel CL-611® NF were added to the formulation. Figure 3 shows the viscosity profile as a result of adding the two excipients, which increases with their increasing concentrations. Table 4 and Figure 5 show that the addition of these excipients did not interfere with the assay or dissolution profile.
In conclusion, Sentry™Polyox™WSR N80, NF and Avicel CL-611® NF increased the suspendability of a water-insoluble API (X) in a reconstitutable powder for oral suspension.